During the last session, Silence Therapeutics Plc ADR (NASDAQ:SLN)’s traded shares were 0.39 million, with the beta value of the company hitting 1.01. At the end of the trading day, the stock’s price was $5.69, reflecting an intraday gain of 5.18% or $0.28. The 52-week high for the SLN share is $27.72, that puts it down -387.17 from that peak though still a striking 15.29% gain since the share price plummeted to a 52-week low of $4.82. The company’s market capitalization is $268.62M, and the average intraday trading volume over the past 10 days was 0.4 million shares, and the average trade volume was 547.72K shares over the past three months.
Silence Therapeutics Plc ADR (SLN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. SLN has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it.
Silence Therapeutics Plc ADR (NASDAQ:SLN) trade information
Silence Therapeutics Plc ADR (SLN) registered a 5.18% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 5.18% in intraday trading to $5.69, hitting a weekly high. The stock’s 5-day price performance is 13.12%, and it has moved by -17.30% in 30 days. Based on these gigs, the overall price performance for the year is -69.73%. The short interest in Silence Therapeutics Plc ADR (NASDAQ:SLN) is 0.35 million shares and it means that shorts have 2.36 day(s) to cover.
The consensus price target of analysts on Wall Street is $55, which implies an increase of 89.65% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $49 and $67 respectively. As a result, SLN is trading at a discount of -1077.5% off the target high and -761.16% off the low.
Silence Therapeutics Plc ADR (SLN) estimates and forecasts
Statistics show that Silence Therapeutics Plc ADR has underperformed its competitors in share price, compared to the industry in which it operates. Silence Therapeutics Plc ADR (SLN) shares have gone down -73.02% during the last six months, with a year-to-date growth rate less than the industry average at -20.69% against 16.80.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -6.72%. While earnings are projected to return -11.46% in 2025, the next five years will return -15.00% per annum.
SLN Dividends
Silence Therapeutics Plc ADR is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Silence Therapeutics Plc ADR (NASDAQ:SLN)’s Major holders
Silence Therapeutics Plc ADR insiders own 16.94% of total outstanding shares while institutional holders control 62.77%, with the float percentage being 75.57%. TCG CROSSOVER MANAGEMENT, LLC is the largest shareholder of the company, while 84.0 institutions own stock in it. As of 2024-06-30, the company held over 3.3 million shares (or 7.4962% of all shares), a total value of $62.61 million in shares.
The next largest institutional holding, with 2.78 million shares, is of ARTAL GROUP S.A.’s that is approximately 6.323% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $52.81 million.
Also, the Mutual Funds coming in first place with the largest holdings of Silence Therapeutics Plc ADR (SLN) shares are Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Tema ETF Tr-Tema GLP-1, Obesity & Cardiometabolic ETF . Data provided on Sep 30, 2024 indicates that Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund owns about 640.0 shares. This amounts to just over 2.14 percent of the company’s overall shares, with a $3.64 million market value. The same data shows that the other fund manager holds slightly less at 76.77, or about 0.26% of the stock, which is worth about $0.44 million.
